Clinical trial
Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia
NCT00003620 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00003620 |
|---|---|
| Title | Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia |
| Official title | A PHASE II STUDY OF FLAVOPIRIDOL (NSC # 649890) IN PATIENTS WITH PREVIOUSLY TREATED BCELL CHRONIC LYMPHOCYTIC LEUKEMIA |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia |
| Intervention type | Drug, Other |
| Interventions | alvocidib, laboratory biomarker analysis |
| Enrollment | 37 |
| Start date | Jun 1, 1999 |
| Primary completion | Jun 1, 2006 |
| First posted | Sep 25, 2003 |
| Last update posted | Jan 17, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: